Abstract: 2-(6,8-Dibromo-2-methylquinazolin-4-yloxy)-acetohydrazide (4) was prepared by the reaction of 6,8-dibromo-2-methylbenzo- [d] [1, 3] oxazin-4-one with formamide to afford quinazolinone 2, followed by alkylation with ethyl chloroacetate to give the ester 3. Treatment of ester 3 with hydrazine hydrate and benzaldehyde afforded 4 and styryl quinazoline 5. The hydrazide was reacted with triethyl orthoformate, acetylacetone and ethyl acetoacetate and benzaldehyde derivatives to afford the corresponding pyrazoles 6, 7, 9 and hydrazone derivatives 10a-c. Cyclization of hydrazones 10a-c with thioglycolic acid afforded the thiazole derivatives 11a-c. Reaction of the hydrazide with isothiocyanate derivatives afforded hydrazinecarbothioamide derivatives 12a-c, which cyclized to triazole-3-thiols and thiadiazoles 13a-c and 14a-c, respectively. Fusion of the hydrazide with phthalimide afforded the annelated compound 1,2,4-triazolo[3,4-a]isoindol-5-one (15). The newly synthesized compounds were characterized by their spectral (IR, 1 H-, 13 C-NMR) data. Selected compounds were screened for analgesic activity.
Introduction
Quinazolin-4(3H)-one and its derivatives are a class of heteroaromatic compounds that have drawn much attention due to their biological and pharmaceutical activities [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . A brief survey on the biological activities of quinazolin-4(3H)-one derivatives showed anti-inflammatory [12] [13] [14] , antitumor [15] [16] [17] [18] , anti HIV [19] , antibacterial [20] [21] [22] , as well as CNS depressant and anticonvulsant activities [23, 24] . 4-Substituted quinazolines were also studied as anticancer agents for their strong ability to inhibit several receptor tyrosine kinases [25] . Derivatives of quinazolin-4-one are potential drugs which can possess hypnotic [26] , analgesic [27] , anthelmintic [28] , neuroleptic [29] , antiallergic, antimalarial and other effects [30, 31] . On the other hand, it was found that not only quinazoline derivatives showed chemotherapeutic activity, but also pyrazole [32] , pyrazolone [33] , thiadiazoles [34] as well as triazole [35, 36] moieties possess this activity. Moreover, the increasing biological importance of quinazolinone derivatives particularly in chemotherapy, promoted us to develop and synthesize the new pyrazolone, pyrazole, thiazolidine, triazole, thiadiazole and triazolo [3,4-a] isoindole molecules with a 6,8-dibromoquinazoline substituent moiety, with the aim of obtaining some novel heterocyclic systems with potentially enhanced biological properties.
Chemistry
In the view of high biological and pharmacological activity of quinazoline derivatives, we reported in previous work certain substituted quinazoline derivatives [37] , so we aimed to continue the previous study in this work. 6,8-Dibromo-2-methyl-4H-benzo[d] [1, 3] oxazin-4-one (1) was refluxed with formamide to produce 6,8-dibromo-2-methylquinazolin-4(3H)one (2) . Reaction of compound 2 with ethyl chloroacetate in dry acetone in presence of potassium carbonate afforded ethyl 2-(6,8-dibromo-2-methylquinazolin-4-yloxy)acetate (3) . Hydrazinolysis of compound 3 with hydrazine hydrate gave the corresponding 2-(6,8-dibromo-2-methylquinazolin-4-yloxy)acetohydrazide (4), which was used as starting material for preparation of some other quinazoline derivatives (Scheme 1). The IR spectrum of compound 2 showed bands at 3,350, 1,685 and 1,620 cm The synthesis of pyrazolone 6 and pyrazole derivatives 7, as outlined in Scheme 2, involved treating 2-(6,8-dibromo-2-methylquinazolin-4-yloxy)acetohydrazide (4) with triethyl orthoformate and acetyl-acetone, respectively. The IR spectrum of compound 6 showed bands at 3,285, 1,685 cm Treatment of compound 4 with p-substituted benzaldehyde in absolute ethanol afforded benzylidine hydrazide derivatives 10a-c, which were cyclized in the presence of thioglycolic acid to obtain thiazolidine derivatives 11a-c, respectively (Scheme 2). The structure of compounds 10a-c was characterized by the presence of bands between 3,280-3,290 and 1,680-1,685 cm The new triazole and thiadiazole derivatives 13a,b and 14a,b were obtained from the reactions of the starting hydrazide 4. Reaction of compound 4 with phenyl and cyclohexyl isothiocyanate gave hydrazinecarbothioamide derivatives 12a,b, which was followed by their cyclization using 5% Na 2 CO 3 solution to form 13a,b and with conc. H 2 SO 4 to give 14a,b, as reported in the literature [38] 3 , CH 2 O and SH groups. In compounds 14a and 14b, the IR spectra gave the absorption bands at 3,280 and 1,618-1620 cm 
Pharmacological Studies

Analgesic Activity
Analgesic activity was examined by using the hot-plate test protocol [40, 41] . Sixty Webster mice of both sexes weighting 20-25 g are used for study. All animals were fed diet in pellets following standard good laboratory practices. Mice were maintained under 12 h light/dark cycles with controlled temperature (22 °C) . Experiments were performed in accordance with the standard institutional ethical guidelines. After incubation period (one weak) mice were classified into ten groups. One group as negative control received saline, the second group received vehicle (acacia gum) and the third group received valdecoxib (g) as a reference drug, while the other groups received the nine test compounds by subcutaneous infusion (SC administration). Mice were dropped gently in a dry glass beaker of 1 dm 3 capacity maintained at 50-50.5 °C. Normal reaction time in seconds for all mice was determined at time intervals of 10, 30, 60 and 120 minutes, this is the interval extending from the instant the mouse reaches the hot beaker till the animals licks its feet or jump out the beaker (dose 5 mg/kg) [39] . The relative potencies to valdecoxib (g) were then determined (Table 1) . 
Results
All the tested compounds exhibited more potent analgesic activity than valdecoxib(g) as a reference drug (Table 1) . Compounds 7, 13a, 13b, 14a and 14b showed more than twice the activity of Valdecoxib(g) after two hours.
Experimental
Melting points are uncorrected and were recorded in open capillary tubes on a Stuart SMP3 melting point apparatus. Infrared spectra were recorded on a FTIR 1600 spectrophotometer using KBr discs. (6) . A mixture of 4 (10 mmol) and triethyl orthoformate (16 mL) with a few drops of acetic acid was refluxed for 2 h. After cooling the reaction mixture was poured onto water. The solid obtained was filtered off, dried and crystallized from ethanol to give colorless crystals. Yield 95%; m.p.: 168-170 °C. IR (KBr): 3,285 cm 
4-(6,8-Dibromo-2-methylquinazolin-4-yloxy)-1H-pyrazol-5(4H)-one
2-(6,8-Dibromo-2-methylquinazolin-4-yloxy)-1-(3,5-dimethyl-1H-pyrazol-1-yl)ethanone (7)
. A mixture of 4 (10 mmol) and acetylacetone (10 mmol) in acetic acid (10 mL) was refluxed for 6 h. After cooling, the reaction mixture was poured onto ice-water. (8) . A mixture of 4 (10 mmol) and ethyl acetoacetate (10 mmol) in acetic acid (10 mL) was refluxed for 5 h, cooled and the reaction mixture was poured onto ice-water to give a colorless powder which was crystallized from ethanol/acetic acid. Yield 75%; m. (9) . A solution of 8 (10 mmol) in sodium hydroxide (10%, 20 mL) was boiled under reflux for 6 h, then the reaction mixture was poured onto ice-water and neutralized with dilute HCl. 
Ethyl 3-(2-(2-(6,8-dibromo-2-methylquinazolin-4-yloxy)acetyl) hydr-azono)butanoate
1-(2-(6,8-Dibromo-2-methylquinazolin-4-yloxy)acetyl)-3-methyl-1H-pyrazol-5(4H)-one
General Procedure for the Synthesis of Compounds 10a-c
A mixture of 4 (10 mmol) and benzaldehyde derivatives (10 mmol) in absolute ethanol (10 mL) and a few drops of acetic acid was refluxed for 10 h, and the reaction mixture left to cool. The colorless solid was filtered off, and crystallized from ethanol/acetic acid. 
N'-Benzylidine-2-(6,8-dibromo-2-methylquinazolin-4-yloxy)acetohydrazide (10a)
.
2-(6,8-Dibromo-2-methylquinazolin-4-yloxy)-N'-(4-methoxyben-zylidine)-acetohydrazide (10c
General Procedure for the Synthesis of Compounds 11a-c
A mixture of 10a-c (10 mmol) and thioglycolic acid (10 mmol) in dry pyridine (10 mL) was refluxed for 6 h, cooled, and the reaction mixture was poured onto cold dil. HCl. The solid obtained was filtered off, and crystallized from ethanol. (6,8-Dibromo-2-methylquinazolin-4-yloxy)-N-(4-oxo-2-phenyl-thiazolidin-3-yl) 
2-
2-(6,8-Dibromo-2-methylquinazolin-4-yloxy)-N-(2-(4-methoxyph-enyl)4-oxothiazolidin-3-yl)acetamide (11c
2-(2-(6,8-Dibromo-2-methylquinazolin-4-yloxy)acetyl)-N-phenylh-ydrazineecarbothioamide (12a)
N-Cyclohexyl-2-(2-(6,8-dibromo-2-methylquinazolin-4-yloxy)ac-etyl)hydrazinecarbothioamide (12b).
A mixture of 4 (10 mmol) cyclohexyl isothiocyanate (10 mmol) in dry dioxane (20 mL 
General Procedure for the Synthesis of 13a,b
Compounds 12a,b (1.0 g) were refluxed in 5% Na 2 CO 3 solution (10 mL) for 5 h. The mixture was left to cool, filtered, and the filtrate was acidified with dil. HCl. The solid obtained was filtered off, and crystallized from ethanol to give colorless crystals. 
5-((6,8-Dibromo-2-methylquinazolin-4-yloxy)methyl)-4-phenyl-4H-1,2,4-triazole-3-thiol (13a
General Procedure for the Synthesis of 14a,b
Compounds 12a,b (1.0 g) were stirred at 5 °C for 1 h in conc. H 2 SO 4 (20 mL) then the reaction mixture was left to stir at room temperature for another 15 h. The reaction mixture was poured onto ice-water; the solid obtained was filtered off, washed with water, dried and crystallized from ethanol/acetic acid. (15) . A mixture of 4 (10 mmol) and phthalimide (10 mmol) was fused in an oil bath at 180 °C for 3 h. After cooling the reaction mixture was poured onto ice-cold HCl. The solid obtained was filtered off, washed with water and crystallized from ethanol/acetic acid to give a pale brown powder. Yield 81%; m. 
5-((6,8-Dibromo-2-methylquinazolin-4-yloxy)methyl)-N-phenyl-1,3,4-thiadiazol-2-amine (14a)
3-((6,8-Dibromo-2-methylquinazolin-4-yloxy)methyl-5H-[1,2,4]-triazolo[3,4-a]isoindol-5-one
Conclusions
We have used simple and convenient methods with simple work up and producing clean products for the synthesis of novel heterocycles such as pyrazolone, pyrazole, thiazole, 1,2,4-triazole and 1,3,4-thiadiazole moieties with 6,8-dibromo-2-methylquinazolin-4(3H)-one as substituent from 2-(6,8-dibromo-2-methylquinazolin-4-yloxy)acetohydrazide. All the compounds tested for analgesic activity showed higher activity than valdecoxib(g) used as a reference drug.
